



GelSana, a Colorado-based medical device company and part of the MedTech Innovator 2025 cohort is developing Cleragel,TM a proprietary next-generation, transparent wound dressing made with patented polymers that repel bacteria, reduce inflammation, and accelerate healing.

RAISING \$10M SERIES A

Chronic and difficult-to-heal wounds remain a major problem. Current treatments are insufficient as they do not address the underlying issue of overactive inflammation in these wounds. Our zwitterionic polymer wound dressings overcome this problem by reducing inflammation to allow the wound bed to proceed to healing. We are raising \$10M to commercialize Cleragel, scale manufacturing, and pursue key clinical studies to demonstrate clear patient benefit.

WHY NOW?

Launching in late 2025, Cleragel is designed to redefine the capabilities of first-line of care dressings and offer a cost-effective alternative to expensive biologic therapies. The U.S. wound care market is at a pivotal moment. Medicare and Medicaid have begun efforts to limit reimbursement for costly biologic and tissue-based products, creating strong demand for effective, affordable alternatives. Cleragel, a first-line of care dressing, shows promising healing and inflammation reduction in difficult wounds in pre-clinical models. Clinical studies are planned to confirm these outcomes in patients.

Introducing Cleragel




Coming late 2025

Advanced Wound Dressing

Conformable and Stretchable
Wound Filler

Novel zwitterionic polymer that has been shown in preclinical data to:

- Reduce inflammation
- Repel bacteria
- Accelerate healing



FUNDING SUMMARY


\$10,00,000 SERIES A (ACTIVE)

\$3,000,000 PRE-SEED AND SEED (CLOSED)

\$2,500,000 AWARDED GRANTS

SERIES A USE OF FUNDS

- MANUFACTURING SCALE-UP
- STRATEGIC COMMERCIAL HIRES
- KEY CLINICAL STUDIES



MARKET SIZE

Advanced Wound Care Market estimated \$14.8B in 2025.

Cleragel has the potential to have a positive impact in healing wounds in each one of these wound types.

COMMERCIAL PLAN

Cleragel will first make an impact in treating diabetic foot ulcers (DFUs), a chronic and costly wound type. From this base, GelSana will expand Cleragel's indications to include venous leg ulcers, pressure ulcers, surgical incisions, trauma injuries and burns — scaling across wound clinics, hospitals, long-term care, and burn centers. A soft launch is planned for 2025–2026, with full US commercialization in 2027 and European expansion to follow.



PIPELINE

Cleragel will be available in two sizes by 2027 to drive expansion into a broader set of wound types and use scenarios.

GelSana is also advancing a severe burn care solution through a Phase II DoD grant, targeting a 2028–2029 launch.

With strong market tailwinds, novel IP, and a clear clinical and commercial path, GelSana is poised to lead a new era in wound care.

Leadership

- Melissa Krebs, PhD, Founder & CEO
- Jon Fernandez, COO
- Adam Rucker, PhD, Director of R&D

Board of Directors

- Mike Freeman, CEO, Innosphere Ventures
- Diana Verilli, Dispatch Health (prev. McKesson)

Advisors

- David Armstrong, PhD, DPM
- John James, MD
- Lisa Gould, MD
- Kathleen Schaum (Reimbursement)

"WE ARE CHANGING HOW WOUNDS ARE HEALED"

-MELISSA KREBS, PHD, CEO